As Table II indicates, oxybutynin XL is the dominant therapeutic option. Not only does it provide superior effectiveness results compared with tolterodine IR, it also leads to lower overall costs.

There were no substantive differencesin the demographic and clinicalcharacteristics in the tolterodine ER versusoxybutynin ER and the tolterodine ER versusoxybutynin IR treatment cohorts (Table 2).The ...

Objective: The objective of this study was tocompare 1-year total healthcare costs for patientswith overactive bladder (OAB) initiating treatmentwith extended-release formulations of tolterodineand ...

Oxybutynin immediate-release oral tablet is used to treat overactive bladder. This form of oxybutynin is available in a generic version only. More common side effects of oxybutynin include being ...

Antimuscarinic drugs are the first-line treatment for overactive bladder. However, traditional formulations are associated with a number of adverse effects, most notably dry mouth. A study comparing a ...

Draft NICE guidelines for urinary incontinence recommend a wider range of antimuscarinic drugs for use first-line in urinary incontinence. The draft guidelines released for consultation this week say ...

Objective: To evaluate the cost-effectiveness of a new extended-release (XL) formulation of oxybutynin relative to tolterodine immediate release (IR), currently the most prescribed treatment for ...